How to Evaluate Mesothelioma Treatment Centers: 4 Criteria That Predict 20% Better Survival

Patients treated at high-volume mesothelioma centers achieve 18-month median survival compared to 15 months at lower-volume facilities—a 20% survival advantage driven entirely by where you receive care, according to a National Cancer Database analysis of surgical outcomes across U.S. cancer centers.^[1] With approximately 3,000 Americans diagnosed with mesothelioma annually, choosing the right treatment center is one of the most consequential decisions a patient will make.^[3]

What Are the Key Facts About Choosing a Mesothelioma Treatment Center?

Why Does Surgical Volume Determine Mesothelioma Treatment Outcomes?

Mesothelioma surgery is among the most technically demanding procedures in thoracic oncology. The diseased pleural lining wraps around the lung, heart, and diaphragm, requiring precise dissection to achieve macroscopic complete resection while preserving organ function. Surgeons who perform this procedure regularly develop the judgment to navigate complex anatomy, manage intraoperative complications, and select appropriate candidates.

The evidence base for the volume-outcome relationship is robust. Simone et al. analyzed mesothelioma surgical cases in the National Cancer Database and found that facilities in the 90th percentile of surgical volume achieved 90-day mortality of 10.0% compared to 14.6% at lower-volume facilities—a 31% relative reduction in perioperative death.^[1] Median overall survival was 18 months at high-volume centers versus 15 months at lower-volume facilities.

The volume effect extends beyond the surgeon's hands. High-volume centers build entire teams around mesothelioma care: specialized thoracic anesthesiologists, intensive care nurses experienced with post-thoracic surgery patients, pathologists who accurately subtype mesothelioma tumors (critical for treatment decisions), and clinical trial coordinators who identify eligible patients for emerging therapies.

"When a patient asks me how to choose a treatment center, the first question I tell them to ask is: how many mesothelioma surgeries do you perform each year? If the answer is fewer than 10, that center does not have the institutional experience to manage the complications and decision-making this disease demands."

How Has the Shift From EPP to P/D Changed Surgical Outcomes?

The mesothelioma surgical landscape has undergone a fundamental paradigm shift over the past two decades. Extrapleural pneumonectomy—which removes the entire affected lung along with the pleura, diaphragm, and pericardium—was once considered the definitive surgical approach. The landmark 663-patient multi-institutional study by Flores et al. (2008) changed that calculus permanently.^[2]

The study found that P/D carried an operative mortality of 4% compared to 7% for EPP. More significantly, multivariate analysis demonstrated that EPP carried a hazard ratio of 1.4 compared to P/D—meaning EPP patients faced a 40% higher risk of death after controlling for stage, histology, gender, and multimodality therapy. This data drove most major mesothelioma treatment centers to adopt P/D as the preferred procedure.

The controversy reignited in 2024 when the MARS 2 randomized trial (Lim et al., published in The Lancet Respiratory Medicine; PMID 38740044) reported no survival advantage for extended P/D over chemotherapy alone, with 9% surgical mortality in the P/D arm.^[8] However, Mount Sinai's February 2026 retrospective analysis of 71 P/D patients directly challenged these findings: 0% 30-day mortality, 4.2% 90-day mortality, and rigorous patient selection including mandatory PET/CT imaging. The Mount Sinai surgeons argued that patient selection criteria, imaging requirements, and surgical approach explain the mortality differences between their results and MARS 2.

"The MARS 2 trial generated headlines, but the experienced centers pushed back with data. Mount Sinai's 0% 30-day mortality in 71 patients tells a different story than MARS 2's 9% mortality. The difference is patient selection and surgical volume—exactly the factors patients need to evaluate when choosing where to be treated."

What Should Patients Look for in an NCI-Designated Cancer Center?

The National Cancer Institute designates cancer centers that meet rigorous standards for research, clinical care, and scientific leadership.^[9] NCI-designated Comprehensive Cancer Centers—the highest designation level—must demonstrate substantial cancer research programs, clinical trials participation, and community outreach. For mesothelioma patients, NCI designation signals several important capabilities.

First, NCI-designated centers are more likely to offer clinical trials for emerging mesothelioma therapies. CheckMate 743 established nivolumab plus ipilimumab as first-line standard of care for unresectable pleural mesothelioma, with a 5-year overall survival rate of 14% versus 6% for chemotherapy.^[4] The next generation of mesothelioma immunotherapy combinations, including CAR T-cell therapy and targeted agents, is being tested primarily at NCI-designated centers.

Second, pathology accuracy is critical. Mesothelioma subtypes—epithelioid, sarcomatoid, and biphasic—have dramatically different prognoses and treatment responses. Epithelioid mesothelioma carries the best surgical prognosis, while sarcomatoid disease is rarely surgical. Experienced pathologists at high-volume centers correctly classify tumors more reliably than pathologists who encounter mesothelioma infrequently.

However, NCI designation alone does not guarantee mesothelioma expertise. Some NCI-designated centers treat very few mesothelioma patients. Patients should verify that the specific center has a named mesothelioma program, publishes outcomes data, and treats sufficient volume to maintain proficiency.

How Do Published Outcomes Data Help Patients Compare Centers?

The gold standard for evaluating a treatment center is peer-reviewed published outcomes data. Centers that publish their surgical results in medical journals subject their data to external review, making it verifiable and comparable. Patients should look for the following data points when reviewing a center's track record:

• Number of patients (n=): Series of 50+ patients provide more reliable data than smaller series.
• 30-day and 90-day mortality: Modern benchmarks for P/D are under 5% for 30-day mortality. Mount Sinai's 0% 30-day mortality sets the current high watermark.
• Median overall survival: For surgical epithelioid mesothelioma patients, 18+ months is the target at high-volume centers.^[1]
• Histology-specific outcomes: Centers should report outcomes separately for epithelioid, biphasic, and sarcomatoid subtypes.
• Study period: Recent data (within 5 years) reflects current surgical techniques and perioperative protocols.

The mesothelioma surgery options guide provides detailed comparisons of surgical approaches. Notable published series include Brigham's 529-patient EPP series (14% 5-year OS for epithelioid; PMID 25203873) and Dr. Friedberg's photodynamic therapy series (74 patients; 36-month median OS overall, 87 months for N0 patients; PMID 27825687).^[6]

"Published data is the single most important tool patients have for comparing centers. If a center claims exceptional results but has not published them in a peer-reviewed journal, those results have not been verified by independent scientists. Ask for the publications. Read the numbers. That is how you make this decision with evidence rather than marketing."

What Role Do Multidisciplinary Tumor Boards Play in Mesothelioma Care?

The National Cancer Institute treatment guidelines specify that mesothelioma care should involve multidisciplinary evaluation by thoracic surgeons, medical oncologists, radiation oncologists, pathologists, and palliative care specialists.^[5] A multidisciplinary tumor board brings these specialists together to review each patient's case and develop a coordinated treatment plan.

For mesothelioma, tumor board review is particularly important because treatment decisions depend on multiple interacting factors: histological subtype, tumor stage, patient age and fitness, pulmonary function, and the presence of specific biomarkers like BAP1 and NF2/merlin status. No single specialist can optimally evaluate all of these factors in isolation.

High-volume centers hold dedicated mesothelioma tumor boards—sometimes weekly—where complex cases are discussed by specialists who see this disease regularly. Lower-volume centers may discuss mesothelioma cases in general thoracic or oncology tumor boards where the specialists may have limited mesothelioma-specific experience.

A 2025 multi-center analysis of 276 long-term mesothelioma survivors (PMID 39447855) confirmed that patients who achieved 5+ year survival after extended pleurectomy/decortication were predominantly epithelioid subtype and treated at high-volume centers with multidisciplinary protocols.^[7] This data reinforces that long-term survival is achievable—but requires the institutional infrastructure that only dedicated programs provide.

How Do Emerging Therapies Factor Into Center Selection?

The mesothelioma treatment landscape is evolving rapidly. Beyond established immunotherapy with nivolumab plus ipilimumab, several emerging approaches are showing promise at specialized centers:

• CAR T-cell therapy: Memorial Sloan Kettering reported 23.9-month median OS for mesothelin-targeted CAR T cells combined with pembrolizumab, with 83% one-year survival and 2 complete metabolic responses.
• Photodynamic therapy: Dr. Friedberg's P/D + PDT program at University of Maryland achieved 36-month median OS, with N0-stage patients reaching 87 months—7.3 years of median survival.^[6]
• FAK inhibitors: The COMMAND trial tested defactinib in 344 patients based on merlin biomarker status, representing a new approach to targeted therapy in mesothelioma.
• Tumor Treating Fields: NovoTTF-100L devices approved for mesothelioma offer a non-systemic treatment modality.

Access to these emerging therapies often depends on geography. Clinical trials are concentrated at major academic centers, and many require travel. The financial resources available through asbestos trust fund claims and legal settlements can help offset travel and lodging costs for patients who need to seek treatment at distant specialized centers.

"Every mesothelioma patient deserves access to the best available treatment, regardless of where they live. The patients who achieve the best outcomes are those who seek care at centers that treat this disease as a specialty, not an occasional diagnosis. If that means traveling, compensation from trust funds and lawsuits can make it possible."

What Is a Practical Framework for Evaluating Mesothelioma Treatment Centers?

Based on the evidence, patients should evaluate mesothelioma treatment centers across four dimensions:

1. Surgical volume: Ask how many mesothelioma surgeries the center performs annually. High-volume is 20+ cases/year. Facilities treating fewer than 5-10 cases/year lack the institutional experience to optimize outcomes.^[1]
2. Published outcomes: Request the center's published surgical series with specific patient numbers, mortality rates, and survival data. Centers without peer-reviewed publications have unverified results.
3. Clinical trial access: Verify that the center has active mesothelioma clinical trials and can enroll eligible patients in NCI-sponsored and industry-sponsored studies.^[9]
4. Multidisciplinary infrastructure: Confirm the center has a dedicated mesothelioma tumor board, experienced pathologists, and supportive services including palliative care, nutrition, and patient navigation.

Second opinions are standard practice in mesothelioma care. Major centers expect and encourage patients to seek additional evaluations before committing to a treatment plan. The NCI maintains a searchable directory of designated cancer centers at cancer.gov.^[9]

Take our free mesothelioma compensation quiz to evaluate your eligibility for trust fund claims, lawsuits, and veterans benefits that can help fund treatment at a specialized center. Call 1-800-692-8608 for a free case evaluation and referrals to experienced mesothelioma treatment centers.

"The data is unambiguous: surgical volume, published outcomes, clinical trial access, and multidisciplinary tumor boards predict better survival. Patients who evaluate centers on these four criteria—rather than convenience or marketing—give themselves the best chance at the longest, highest-quality survival."

References

1. 1. Volume-outcome relationship in mesothelioma surgery (Simone et al.) — Lung Cancer (Elsevier) (2018)
2. 2. EPP versus P/D outcomes (Flores et al.) — Annals of Thoracic Surgery (2008)
3. 3. SEER Cancer Statistics Explorer: Mesothelioma — National Cancer Institute (2025)
4. 4. CheckMate 743: Nivolumab plus Ipilimumab — The Lancet (2021)
5. 5. Mesothelioma Treatment (PDQ) — National Cancer Institute (2025)
6. 6. Photodynamic therapy with pleurectomy (Friedberg et al.) — Annals of Thoracic Surgery (2017)
7. 7. Long-term survivors of pleural mesothelioma after surgery — Annals of Thoracic Surgery (2025)
8. 8. MARS 2 Trial — The Lancet Respiratory Medicine (2024)
9. 9. NCI-Designated Cancer Centers — National Cancer Institute (2025)
10. 10. Mesothelioma Mortality in the United States — Centers for Disease Control and Prevention (2025)
11. 11. Mesothelioma Treatment Centers — WikiMesothelioma
12. 12. Mesothelioma Quick Facts — WikiMesothelioma
13. 13. Immunotherapy for Mesothelioma — WikiMesothelioma